The following details were available for trading and market data about the stock of AbbVie as of writing:
Trading Details of AbbVie (ABBV)
Current Share Price:
Previous Year's Closing Price:
Percentage Price Change (YTD):
52-week Price Range:
$105.56 - $175.91
Dividend Per Share:
Company Profile and Business Description for AbbVie
AbbVie Inc. (AbbVie), incorporated on April 10, 2012, is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.
HUMIRA is a biologic therapy administered as a subcutaneous injection. It is approved to treat the autoimmune diseases, such as Rheumatoid arthritis (moderate to severe), Psoriatic arthritis, Ankylosing spondylitis, Adult Crohn's disease (moderate to severe), Plaque psoriasis (moderate to severe chronic), Ulcerative colitis (moderate to severe), Pediatric Crohn's disease (moderate to severe), Hidradenitis Suppurativa (moderate to severe), non-infectious intermediate, posterior and panuveitis, and Juvenile idiopathic arthritis (moderate to severe polyarticular) in North America and the European Union. It is also approved to treat the autoimmune diseases, such as Axial spondyloarthropathy and Pediatric enthesitis-related arthritis in the European Union. It is also approved in Japan for the treatment of intestinal Behcet's disease.
AbbVie's oncology products targets cancers, including hematologic and solid cancers. These products include IMBRUVICA (ibrutinib) and Venclexta (venetoclax). IMBRUVICA is an oral and once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). It is approved for the treatment of patients with chronic lymphocytic leukemia (CLL). It is also approved for the treatment of patients with mantle cell lymphoma (MCL), who have received at least one prior therapy. It also treats patients with relapsed/refractory marginal zone lymphoma (MZL). Venclexta is approved to treat people with chronic lymphocytic leukemia (CLL). It is approved for the treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth.
The Company's Virology products address the needs for patients with the HCV and HIV-1. Its HCV product, VIEKIRA PAK (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), which is an all-oral, short-course, interferon-free therapy, with or without ribavirin, for the treatment of adult patients with genotype 1 chronic HCV, including those with compensated cirrhosis. In Europe, its HCV treatment is marketed as VIEKIRAX + EXVIERA and is approved for use in patients with genotype 1 and genotype 4 HCV. AbbVie's TECHNIVIE (ombitasvir, paritaprevir and ritonavir) is also approved for use in combination with ribavirin for the treatment of adults with genotype 4 HCV infection in the United States.
The Company's additional virology products include Kaletra (lopinavir/ritonavir), Norvir (ritonavir) and Synagis (palivizumab). Kaletra is a prescription anti-HIV-1 medicine that contains two protease inhibitors: lopinavir and ritonavir. It is used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1. Norvir is a protease inhibitor that is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Synagis is a product marketed by AbbVie outside of the United States that protects at-risk infants from severe respiratory disease caused by respiratory syncytial virus (RSV).
The Company's metabolic and hormone products target various conditions, including testosterone deficiency due to certain underlying conditions, exocrine pancreatic insufficiency and hypothyroidism. These products include AndroGel (testosterone gel), Creon (pancrelipase) and Synthroid (levothyroxine sodium tablets). AndroGel is a testosterone replacement therapy for males diagnosed with symptomatic low testosterone due to certain underlying conditions. Creon is a pancreatic enzyme therapy for exocrine pancreatic insufficiency, a condition that occurs in patients with cystic fibrosis, chronic pancreatitis and several other conditions. Synthroid is used in the treatment of hypothyroidism. It has the rights to sell these products only in the United States.
AbbVie's endocrinology product, Lupron (leuprolide acetate), which is also marketed as Lucrin and Lupron Depot, is a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty and for the preoperative treatment of patients with anemia caused by uterine fibroids. Lupron is approved for daily subcutaneous injection and one-month, three-month, four-month and six-month intramuscular injection.
The Company's other products include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab). Its levodopa-carbidopa intestinal gel for the treatment of advanced Parkinson's disease is marketed as Duopa in the United States and as Duodopa outside of the United States. Sevoflurane, which is sold under the trademarks Ultane and Sevorane, is an anesthesia product that it sells around the world for human use. ZINBRYTA is a once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (MS).
1 N Waukegan Rd
ETFs Holding AbbVie Stock
As of March 2020, the following exchange-traded funds (ETF) hold the AbbVie stocks in their respective portfolios. Below is a random list of only 10 ETFs in no particular order that have AbbVie stock holding. There are a total of 186 ETFs in Fknol.com records which are holding AbbVie stock in their portfolio. See Full List.
The iShares MSCI ACWI ETF tracks a market-cap-weighted index of large- and midcap global stocks, covering 85% of the developed and emerging markets capitalization. ...Full Details ...Candlestick Patterns.
The Global X S&P 500 Catholic Values ETF tracks an index of US large-cap stocks selected from the S&P 500. The cap-weighted index omits companies from certain industries at odds with Catholic values. ...Full Details
▶ Abeona Therapeutics (ABEO): Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., incorporated on June 22, 1989, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Companys lead ....See Detailed Company Profile, Dividend History
▶ AC Immune SA (ACIU): AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimers and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinsons, and ....See Detailed Company Profile, Dividend History
▶ ACADIA Pharma (ACAD): ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. The ....See Detailed Company Profile, Dividend History
▶ Acasti Pharma (ACST): Acasti Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing, clinically studying and marketing new pharmaceutical products to treat human cardiovascular conditions. The Company is involved ....See Detailed Company Profile, Dividend History
▶ AcelRx Pharma (ACRX): AcelRx Pharmaceuticals, Inc., incorporated on July 13, 2005, is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company ....See Detailed Company Profile, Dividend History
▶ Achillion Pharma (ACHN): Achillion Pharmaceuticals, Inc., incorporated on August 5, 1998, is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and ....See Detailed Company Profile, Dividend History
▶ Aclaris Therapeutics (ACRS): Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological ....See Detailed Company Profile, Dividend History
▶ Actinium Pharma (ATNM): Actinium Pharmaceuticals, Inc. (Actinium), incorporated on March 20, 2013, is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its ....See Detailed Company Profile, Dividend History
▶ Acura Pharma (ACUR): Acura Pharmaceuticals, Inc., incorporated on April 10, 1935, is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication ....See Detailed Company Profile, Dividend History
▶ Adamas Pharma (ADMS): Adamas Pharmaceuticals, Inc., incorporated on November 15, 2000, is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic ....See Detailed Company Profile, Dividend History
▶ Adamis Pharma (ADMP): Adamis Pharmaceuticals Corporation, incorporated on April 22, 2004, is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products ....See Detailed Company Profile, Dividend History
▶ Aduro Biotech (ADRO): Aduro Biotech, Inc., incorporated on May 5, 2011, is an immunotherapy company. The Company focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, ....See Detailed Company Profile, Dividend History
▶ Advaxis (ADXS): Advaxis, Inc., incorporated on February 28, 2002, is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are ....See Detailed Company Profile, Dividend History
▶ Aeglea BioTherapeutics (AGLE): Aeglea BioTherapeutics, Inc., incorporated on December 16, 2013, is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to ....See Detailed Company Profile, Dividend History
▶ AEterna Zentaris (AEZS): Aeterna Zentaris Inc., incorporated on October 12, 1990, is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and womens health. The Company operates through the ....See Detailed Company Profile, Dividend History
▶ Affimed (AFMD): Affimed N.V., incorporated on May 1, 2014, is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Companys product candidates are developed in the field of immuno-oncology, ....See Detailed Company Profile, Dividend History
▶ Agile Therapeutics (AGRX): Agile Therapeutics, Inc., incorporated on December 5, 1997, is a womens health specialty pharmaceutical company. The Company is focused on the development and commercialization of prescription contraceptive products. Its product ....See Detailed Company Profile, Dividend History
▶ Agios Pharma (AGIO): Agios Pharmaceuticals, Inc., incorporated on August 7, 2007, is a clinical-stage biopharmaceutical company. The Companys therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group ....See Detailed Company Profile, Dividend History
▶ Aimmune Therapeutics (AIMT): Aimmune Therapeutics, Inc., incorporated on June 24, 2011, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other ....See Detailed Company Profile, Dividend History